Novo Nordisk released data from a late-stage clinical trial that indicated semaglutide better known by its brand name Ozempic reduced the risk of death in diabetes patients with chronic kidney disease (CKD).

Published in theNew England Journal of Medicineon Friday morning,the multi-year study determined that the risk of a primary-outcome event such as major kidney disease events, kidney failure or death was 24% lower in the group that received Ozempic than participants in the placebo group.

Novo stated that the trial met its secondary endpoints, including a less steep mean annual estimated glomerular filtration rate as well as a lower risk of major adverse cardiovascular events (MACE) and risk of death from any cause.

Additionally, a lower percentage of serious adverse events were reported in the semaglutide group than the placebo group. More detailed data from the study was presented at the European Renal Association meeting in Stockholm.

This trial represents the promise of potential label expansion that Ozempic, which is indicated for treating type 2 diabetes, and other GLP-1 drugs could have beyond treating diabetes and obesity.

While GLP-1 drugs have taken off in popularity due to widespread off-label use for weight loss which has caused rampant, lingering shortages both Novo and rival Eli Lilly have been studying this class potential use in other therapeutic areas.

Thus far, the results have been encouraging and led to substantive insurance coverage changes.

Last August, Novo announced that its once-weekly semaglutide 2.4 mg treatment for obesity known by the brand name Wegovy cut the risk of MACE by 20% in a clinical trial. A studyreleased a few weekslater reiterated that semaglutide treatment led to large reductions in heart failure-related symptoms for adults with the condition and obesity.

Based on these clinical trials, the Food and Drug Administration approved a label expansion for Wegovy to be used as a treatment in heart disease this spring. One week after that, the Centers for Medicare and Medicaid Services announced that Medicare Part D plans could cover anti-obesity drugs like Wegovy.

Ozempic and Wegovy have also served as financial juggernauts for the Danish drugmaker, which saw sales rise 24% in Q1, thanks to diabetes and obesity care sales jumping 27% and GLP-1 diabetes products contributing 32% sales growth.

While Novos stock was trading down slightly after the studys release, it served as a boon for dialysis providers like Fresenius, DaVita and FMC.

Here is the original post:
Novo Nordisk's Ozempic slashed risk of death in diabetes patients with CKD - MM+M Online

BATAVIA, Ohio A woman will spend nearly a decade in prison after her 4-year-old child died from severe malnutrition, her teeth rotted out.

A judge sentenced Tamara Banks to nine years in prison on Friday morning. Christopher Hoeb, also charged in the child's death, awaits sentencing on June 11.

Banks was convicted of one count of involuntary manslaughter after the Clermont County coroner determined the girl's cause of death was diabetic ketoacidosis, a life-threatening condition that affects people with diabetes. Prosecutors said the girl had diabetes "that was left undiagnosed and untreated over a long period of time."

According to the prosecution, the girl was found unresponsive on Jan. 21, 2022. The couple called 911 and the girl was taken to a hospital. She was eventually declared to be brain dead and ultimately taken off life support.

Prosecutors said the girl died as a direct result of neglect and abuse from her parents, Hoeb and Banks.

Diabetic ketoacidosis, or DKA, is an extreme complication of untreated diabetes, said Dr. Chris Peltier, President of the Ohio Chapter of the American Academy of Pediatrics.

Peltier said the condition is not necessarily uncommon among children. He said the onset of diabetes can come quickly and children can get sick quickly. However, left untreated, the condition can cause a coma or even death, he said.

Eventually, the body will just shut down, he said.

Prosecutors also claim Banks and Hoeb fed their daughter mostly Mountain Dew through a baby bottle. When she died, the 4-year-old girl had almost no teeth left in her mouth, because they'd rotted out, prosecutors said.

Prosecutors: Young girl died of diabetes after neglect, abuse from parents

Read this article:
Woman sentenced to prison for 4-year-old's malnutrition death - WCPO 9 Cincinnati